IRCT20190504043464N1
Completed
Phase 1
Investigation of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Containing Codon-Optimized Full-Length E7 and E6 Oncoproteins of HPV-16 in Healthy Women
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Iran University of Medical Sciences
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\- People Voluntarily Participate in the Research.
- •2\- The Informed Consent Form Is Completed and Signed by the Person or Her companion.
- •3\- Women PCR positive test for Papilloma Virus Infection.
- •4\. Women Don't Have other sexually transmitted diseases.
- •Women Don't be Pregnant
- •6\. Women in Pap smear Test Don't Have Abnormal Conditions.
Exclusion Criteria
- •1\. People Don't Have Cancerous Disease During the Course of Treatment.
- •2\. Failure to Complete a Course of Treatment by Individuals Will Result in Their Exclusion from Study.
- •3\- Getting Pregnant During the Course of Treatment Will Leave Women Out of Study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
Not yet recruiting
Phase 1
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana
Not yet recruiting
Phase 1
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II.Pneumococcal diseaseHealthy VolunteersPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsRPCEC00000243Finlay Institute Vaccine880
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsISRCTN89337058Crucell Switzerland AG (Switzerland)110
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsISRCTN30202688Crucell, Berna Biotech Ltd (Switzerland)110